Fred Hassan was appointed to Prometheus Biosciences' board of directors, the company announced May 17.
Mr. Hassan is director of private equity company Warburg Pincus, and he was previously chair and CEO of Schering-Plough. He also has experience at Pharmacia Corp., Amgen and Precigen. He received his MBA from Harvard Business School in Boston.
Prometheus Biosciences is a biotechnology company focused on diagnostics and treatment of inflammatory bowel disease and other immune-mediated diseases.